Changing Standards in Transplant-Ineligible Patients Newly Diagnosed with Myeloma

Changing Standards in Transplant-Ineligible Patients Newly Diagnosed with Myeloma
Changing Standards in Transplant-Ineligible Patients Newly Diagnosed with Myeloma
CME, CPE
Saad Z. Usmani, MD, FACP
Release Date: November 30, 2020
Expiration Date: November 30, 2021

The treatment of transplant-ineligible patients with newly diagnosed myeloma remains a clinical challenge, but recent developments in novel therapeutic approaches have been shown to improve outcomes in these patients. In this activity, Dr. Usmani reviews the key clinical data in transplant-ineligible, newly diagnosed myeloma, and provides evidence-based recommendations for choosing individualized treatment regimens.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Takeda Oncology.
Begin, Earn CreditView Only, No Credit